Paragon 28 Launches Phantom® Metatarsal Shortening System
24 April 2023 - 10:05PM
Business Wire
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch
of its Phantom® Metatarsal Shortening System which features a first
in-kind intramedullary device for fixation of in-line shortening
osteotomies of the lesser metatarsals. These osteotomies are
preformed to prevent metatarsalgia and floating toe, two of the
most frequently addressed foot and ankle pathologies. The system
includes a patent pending cut guide allowing for increased
precision when performing the correction.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230424005048/en/
Phantom® Metatarsal Shortening System
(Graphic: Business Wire)
Mark Myerson, MD, Phantom® design surgeon, said, "Many implants
are re-iterations of existing products, however the Phantom®
Metatarsal Shortening System is truly unique, innovative, and quite
novel. The ability to precisely and accurately shorten the
metatarsal with simple and rigid fixation will be a tremendous
addition to the management of various forefoot pathologies".
Paragon 28’s CEO, Albert DaCosta, commented, “We set out to
design an implant that addressed the limitations of current
procedures, in particular the soft tissue imbalance associated with
shortening procedures of the lesser metatarsals. We are thrilled to
have accomplished this ambition with the launch of the Phantom®
Metatarsal Shortening System and expect this addition to catalyze
growth in the forefoot segment of our business. We understand the
value that comes from having a comprehensive forefoot portfolio to
pair with our bunion offering allowing facilities and surgeons to
work with a single partner to meet all their forefoot and bunion
needs.”
The Phantom® Metatarsal Shortening System bolsters Paragon 28’s
forefoot and bunion solutions offering, which includes the
TenoTac™, Paratrooper™, HammerTube™, Gorilla® Precision™ Lapidus
Plate, and Phantom® MIS Lapidus Nail. With this comprehensive
portfolio, Paragon 28® provides its customers with a single source
to address their forefoot and bunion needs.
Paragon 28® is grateful for the significant contributions that
Mark Myerson, MD, Jose Sanhudo, MD, and Lew Schon, MD, made in the
design of this system.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device
company exclusively focused on the foot and ankle orthopedic market
and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, forefoot,
ankle, progressive collapsing foot deformity (PCFD) or flatfoot,
Charcot foot and orthobiologics. The company designs products with
both the patient and surgeon in mind, with the goal of improving
outcomes, reducing ailment recurrence and complication rates, and
making the procedures simpler, consistent, and reproducible.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230424005048/en/
Investor Contact: Matt Brinckman Senior Vice President, Strategy
and Investor Relations (720) 912-1332 mbrinckman@paragon28.com
Paragon 28 (NYSE:FNA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Paragon 28 (NYSE:FNA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024